tradepoet
2K posts

tradepoet
@tradepoet
Curious about everything so challenge my bias




@TylerCompiler Strike is not "hugely profitable." Those unaudited claims were made by Mallers to pump the CEP/XXI price back in April 2025, and never repeated for very good legal and SEC reasons. ❌❌🙏




$ARM is my largest holding in my retirement portfolio. Makes up 95% of my $4M account. The other 5% is cash.

@aleabitoreddit Hey Serenity, If you already have a position in $AAOI, and a small bag of $AEHR, what 2-3 other stock would you look to add now/next few weeks to hold for 1+ years? (Excluding $SIVE and the small Asian stocks as not available for me) thanks for all you share!


















I continue to think $HROW is one of the most undervalued / mispriced growth stocks in the entire market. $HROW is down -33% in the past couple weeks, now trading at 15x NTM ev/ebitda... despite management saying CY2026 revenues will be up +32% YoY (midpoint of guidance) and ebitda will be up +45% YoY (midpoint of guidance). Management said multiple times in the shareholder letter and the earnings call that this guidance is conservative. If you are interested in $HROW or already have a position, I strongly encourage you to listen to the CEO from yesterday's presentation at the Leerink Healthcare conference... event.summitcast.com/view/mT9poctHD… During this presentation, Mark (founder & CEO) said their current guidance is "base case" for CY2026. I used to tell my subs that I'm always looking for breadcrumbs... Mark dropped some big ones during this presentation. I'm listening to it for the second time right now. Not only is $HROW expecting approval next month on a new indication, but he said they're presenting data in July for Izeeho that he thinks can 4x their market share. Then he said G-Melt could be in market within the next 18-24 months and has the potential to become their biggest revenue product ever. CEO also said they are doubling the size of their sales teams over the next 3-6 months because the ROI of having better coverage in more markets is just too obvious. Mark continues to say they can get to $250M in quarterly revenues by CY2027 Q4, which implies approx $1B in CY2028 revenues. Right now $HROW is expecting CY2026 ebitda margins of 26%, if anyone knows biopharma companies and margins... as they scale revenues from here, those margins will get much better. It's very possible $HROW has 35-40% ebitda margins in CY2028 at which point they could be generating $350-400M of ebitda... right now the current enterprise value is $1.5B... so it's possible that $HROW is currently trading at just 4x CY2028 ev/ebitda not including all the cash they'll generate over the next few years. I honestly think $HROW has the potential to be a 5-bagger over the next 3 years. NFA. DYOR. *We own $HROW at @FirstWaveFund; as of this morning it's now a top 8 position.






